The December @immunometforum.bsky.social will
take place this Friday with three great early career researcher presenting:
🧵1/4
#immmunosky #immunoology #immunometabolism
take place this Friday with three great early career researcher presenting:
🧵1/4
#immmunosky #immunoology #immunometabolism
December 10, 2024 at 3:54 PM
The December @immunometforum.bsky.social will
take place this Friday with three great early career researcher presenting:
🧵1/4
#immmunosky #immunoology #immunometabolism
take place this Friday with three great early career researcher presenting:
🧵1/4
#immmunosky #immunoology #immunometabolism
If you are interested in doing a PhD in metabolomics/lipidomics this might be for you - www.findaphd.com/phds/project.... Its a chance to use state of the art mass spectrometry imaging to study (and maybe treat) inflammation in adipose tissue at the Rowett Institute with Biotech company Sitryx.
EASTBIO CASE: Inflammatory Fat: Understanding how the immune system drives adipose tissue dysfunction using lipidomics at University of Aberdeen on FindAPhD.com
PhD Project - EASTBIO CASE: Inflammatory Fat: Understanding how the immune system drives adipose tissue dysfunction using lipidomics at University of Aberdeen , listed on FindAPhD.com
www.findaphd.com
December 30, 2024 at 5:42 PM
If you are interested in doing a PhD in metabolomics/lipidomics this might be for you - www.findaphd.com/phds/project.... Its a chance to use state of the art mass spectrometry imaging to study (and maybe treat) inflammation in adipose tissue at the Rowett Institute with Biotech company Sitryx.
Germany's #BoehringerIngelheim could sink up to $500 million into a #partnership with UK start-up #Sitryx focused on a family of #smallmolecule drugs for #autoimmune and #inflammatory diseases.
buff.ly/QiBzfGU
buff.ly/QiBzfGU
February 26, 2026 at 7:00 PM
Germany's #BoehringerIngelheim could sink up to $500 million into a #partnership with UK start-up #Sitryx focused on a family of #smallmolecule drugs for #autoimmune and #inflammatory diseases.
buff.ly/QiBzfGU
buff.ly/QiBzfGU
Feed: "MedCity News"
By: Frank Vinluan on Thursday, February 26, 2026
By: Frank Vinluan on Thursday, February 26, 2026
Boehringer Boosts Pipeline, Adding Oral Small Molecules With Broad Immunology & Inflammation Potential
Boehringer Ingelheim receives rights to oral small molecules from Sitryx with potential applications in multiple autoimmune disorders. Depending on the progress of Boehringer’s research, Sitryx could receive more than $500 million.
medcitynews.com
February 27, 2026 at 1:00 AM
Feed: "MedCity News"
By: Frank Vinluan on Thursday, February 26, 2026
By: Frank Vinluan on Thursday, February 26, 2026
Feed: "Endpoints News"
By: ENDPOINTS on Monday, August 11, 2025
By: ENDPOINTS on Monday, August 11, 2025
Sitryx gets back rights to drug from Lilly deal; Humacyte is cutting costs
Sitryx regains rights from Lilly for SYX-1042, Humacyte cuts 30 jobs, Equillium gets $50M financing for EQ504, and Ocugen raises $20M from Janus Henderson Investors.
endpoints.news
August 11, 2025 at 3:18 PM
Feed: "Endpoints News"
By: ENDPOINTS on Monday, August 11, 2025
By: ENDPOINTS on Monday, August 11, 2025
We are delighted that we have been shortlisted for a Business Weekly award in the Collaboration of the Year Category based on our work with Sitryx. We supported Sitryx’s MTHFD2 programme which resulted in SIT047, a novel, oral inhibitor, progressing to clinical development for psoriatic arthritis.
July 31, 2025 at 9:31 AM
We are delighted that we have been shortlisted for a Business Weekly award in the Collaboration of the Year Category based on our work with Sitryx. We supported Sitryx’s MTHFD2 programme which resulted in SIT047, a novel, oral inhibitor, progressing to clinical development for psoriatic arthritis.
LucidQuest Views >>> Lucid Diligence Brief: Boehringer Ingelheim & Sitryx Therapeutics autoimmune deal Comment below! #LucidQuest #PharmaCI
Lucid Diligence Brief: Boehringer Ingelheim & Sitryx Therapeutics autoimmune deal
Lucid Diligence Brief: Boehringer Ingelheim & Sitryx Therapeutics autoimmune deal Professional audiences only. Not investment research or advice. UK readers: […]
The post Lucid Diligence Brief: Boehringer Ingelheim & Sitryx Therapeutics autoimmune deal appeared first on LucidQuest Ventures.
dlvr.it
February 27, 2026 at 8:35 AM
LucidQuest Views >>> Lucid Diligence Brief: Boehringer Ingelheim & Sitryx Therapeutics autoimmune deal Comment below! #LucidQuest #PharmaCI
Thoughts on this? >> Sitryx gets back rights to drug from Lilly deal; Humacyte is
cutting costs >> Comment below! #strategy #competitiveintelligence #marketing #biotech #productmarketing #pharmaceutical #healthcare #pharma
cutting costs >> Comment below! #strategy #competitiveintelligence #marketing #biotech #productmarketing #pharmaceutical #healthcare #pharma
Sitryx gets back rights to drug from Lilly deal; Humacyte is
cutting costs
Plus, news about Equillium and Ocugen: Sitryx Therapeutics regains rights to itaconate mimetic: The company had inked a deal with Eli Lilly in 2020 to work on immunometabolic medicines. It
dlvr.it
August 11, 2025 at 4:01 PM
Thoughts on this? >> Sitryx gets back rights to drug from Lilly deal; Humacyte is
cutting costs >> Comment below! #strategy #competitiveintelligence #marketing #biotech #productmarketing #pharmaceutical #healthcare #pharma
cutting costs >> Comment below! #strategy #competitiveintelligence #marketing #biotech #productmarketing #pharmaceutical #healthcare #pharma
Boehringer bets on immunometabolism with $500M-plus Sitryx pact firstwordpharma.com/story/7116016
February 26, 2026 at 10:42 PM
Boehringer bets on immunometabolism with $500M-plus Sitryx pact firstwordpharma.com/story/7116016